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New insights in the expression 
of stromal caveolin 1 in breast 
cancer spread to axillary lymph 
nodes
Cristian Scatena1,2,5*, Giovanni Fanelli2,5, Giuseppe Nicolò Fanelli1, Michele Menicagli3, 
Paolo Aretini3, Valerio Ortenzi2, Sara Piera Civitelli1, Lorenzo Innocenti1, Federica Sotgia4, 
Michael P. Lisanti4 & Antonio Giuseppe Naccarato1,2
Recent evidence suggests that a loss of expression of caveolin in the stromal compartment (sCav-
1) of human invasive breast carcinoma (IBC) may be a predictor of disease recurrence, metastasis 
and poor outcome. At present, there is little knowledge regarding the expression of sCav-1 at the 
metastatic sites. We therefore studied sCav-1 expression in IBCs and in their axillary lymph nodes to 
seek a correlation with cancer metastasis. 189 consecutive invasive IBCs (53 with axillary lymph node 
metastases and 136 without) were studied by immunohistochemistry, using a rabbit polyclonal anti-
Cav-1 antibody. In IBCs sCav-1 was evaluated in fibroblasts scattered in the tumor stroma whereas 
in lymph nodes sCav-1 was assessed in fibroblast-like stromal cells. For the first time, we observed a 
statistically significant progressive loss of sCav-1 from normal/reactive axillary lymph nodes of tumors 
limited to the breast to metastatic axillary lymph nodes, through normal/reactive axillary lymph 
nodes of tumors with axillary metastatic spread. These data indicate that Cav-1 expressed by the 
stromal compartment of lymph nodes, somehow, may possibly contribute to metastatic spread in IBC.
Breast cancer is a heterogeneous disease, the most frequent malignant tumor in women worldwide, with more 
than 2 million new cases and nearly 630.000 estimated deaths in  20181. Studies have traditionally focused on 
elucidation of the events arising in the cancerous epithelial cells with little attention to the role of the surrounding 
stroma or  microenvironment2. At present, fibroblasts, blood vessels and extracellular components are thought 
to be key regulators of cancer progression. Indeed, modified fibroblasts, the so-called “cancer associated fibro-
blasts” (CAFs), modulate extracellular matrix  degradation3 and regulate proliferation of the epithelial cancer cells 
within the primary tumor site, via the production of numerous growth factors and cytokines, including HGF, 
EGF, IGFs, IGFBPs, b-FGF and TGF-β4. The tumor microenvironment likely plays a role also at metastatic sites, 
to re-establish the conditions that disseminated tumor cells (DTCs) require for  growth5. The term “metastatic 
niche” has been coined to refer to this phenomenon and has been described for visceral secondary sites but 
also for lymph nodes: here, fibroblast-like stromal cells, together with bone marrow derived cells, play a crucial 
role to form these permissive  compartments6. At present, the precise complex mechanisms through which the 
stroma orchestrates tumor progression are not fully elucidated. In recent decades, increasing attention has been 
paid to the expression of caveolin-1 (Cav-1) in the tumor microenvironment. Cav-1 is the essential constituent 
protein of caveolae, specialized flask-shaped invaginations of the plasma membrane, that act as signal transduc-
tion hubs by providing compartmentalization of intracellular signaling  molecules7. Cav-1 is expressed on the 
cell membrane of endothelial cells, adipocytes, smooth muscle cells and type 1 pneumocytes. Inside caveolae, 
Cav-1 binds to G-protein subunits, tyrosine kinases and endothelial nitric oxide synthase, thus regulating several 
signaling  pathways8. Mouse models studies demonstrated that caveolins play an important role in a number of 
human diseases such as atherosclerosis, muscular dystrophy, diabetes and  cancer9. The role for this protein in 
the process of cell transformation was reported in 1989, when Cav-1 was identified as a substrate for v-Src in 
transformed chicken embryo  fibroblasts10. Later research suggested Cav-1 gene as tumor suppressor as well as 
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proto-oncogene: downregulation is associated to colon and ovarian carcinomas or sarcomas instead upregulation 
to prostate, lung, esophageal, bladder and papillary thyroid  carcinomas11.
In breast cancer, Cav-1 gene has been suggested as tumor  suppressor12; however, aggressive breast cancer 
subtypes overexpress Cav-1 protein, supporting an oncogenic  role13. Thus, the role of Cav-1 in tumorigenesis 
remains contentious. Interestingly, a number of recent studies have investigated the role of Cav-1 in the tumor 
microenvironment, describing stromal Cav-1 (sCav-1) as a marker of the CAF phenotype in human breast 
 cancer14. In particular, the decreased expression of sCav-1 is associated with poor  prognosis15–17. Loss of sCav-1 
also predicts poor  outcome18, in particular in the subgroup of basal-like breast  cancers19. In addition, a striking 
correlation between loss of sCav-1 and early progression from in situ to invasive breast carcinoma has recently 
been  reported20. However, most of the studies have concentrated so far on sCav-1 in primary tumor and there is 
little knowledge about the expression of sCav-1 at the metastatic sites, in breast cancer or in other tumor models. 
The aim of this study was to investigate the expression of Cav-1 in: i) the stromal compartment of axillary lymph 
nodes of breast cancer patients, to seek a correlation with cancer metastasis; ii) in the stroma of invasive breast 
carcinomas (IBCs), to confirm data from published studies.
Results
Expression of sCav-1 in lymph nodes. We evaluated the expression of sCav-1 in the stromal compart-
ment of lymph nodes (see Fig. 1) which is composed of: (i) fibroblast-like stromal cells, a heterogenous popula-
tion that looks like fibroblasts (with spindle shape cytoplasm and elongated nucleus) which encompasses mar-
ginal reticular cells under the subcapsular sinus and fibroblastic reticular cells in the paracortex/T cell zone; (ii) 
follicular dendritic cells in lymphoid follicles (with several cytoplasmic extensions/dendrites); (iii) endothelial 
cells and (iv) pericytes. These cells have distinctive locations and different functions, some of which not yet fully 
elucidated.
According to our knowledge, to date a specific immunomarker for each fibroblast-like stromal cells is lack-
ing, and their identification mostly relies on location and morphologic features by which they can be easily 
distinguished from lymphocytic cells, plasma cells and monocytes/macrophages.
Among axillary lymph nodes of IBC cases, 119 (65.4%) showed expression of sCav-1 in fibroblast-like stromal 
cells scattered within lymphoid tissue (see Fig. 2d,e,f and Table 1 for details).
All normal/reactive axillary lymph nodes of patients included as negative controls (NC) were positive: 17 
with score 1 and 3 with score 2 (see Fig. 3b). Instead, a large number of metastatic axillary lymph nodes (Ln +) 
(26 out of 54, 48%) showed a loss of sCav-1 expression: sCav-1 was significantly less expressed in metastatic 
axillary lymph nodes (Ln +) than in normal/reactive axillary lymph nodes (Ln−) (p-value = 0.0042) (see Fig. 3a 
for details). In particular, the difference was strikingly more evident between metastatic axillary lymph nodes 
(Ln +) and normal/reactive axillary lymph nodes of tumors limited to the breast (Ln−/IBCN−) (p-value < 0.0001); 
normal/reactive axillary lymph nodes of tumors with axillary metastatic spread (Ln−/IBCN +) showed an in-
between sCav-1 profile: higher if compared to metastatic axillary lymph nodes (Ln +) (p-value = 0.0001) and 
lower if compared, instead, to normal/reactive axillary lymph nodes of tumors limited to the breast (Ln−/IBCN−) 
(p-value < 0.0001) (see Fig. 3b). Axillary lymph nodes of NC showed a sCav-1 expression higher than nor-
mal/reactive axillary lymph nodes of tumors with axillary metastatic spread (Ln−/IBCN +) (p-value = 0.0004) 
and slightly lower than normal/reactive axillary lymph nodes of tumors limited to the breast (Ln−/IBCN−) 
(p-value = 0.0305, Fig. 3b). These results indicate that axillary lymph nodes express high levels of sCav-1, but 
metastatic axillary lymph nodes (Ln +) express lower levels of sCav-1 compared to normal/reactive axillary 
lymph nodes (Ln−); intriguingly, among normal/reactive axillary lymph nodes those close to metastatic lymph 
nodes (Ln−/IBCN +) express lower levels of sCav-1 if compared to those from tumors limited to the breast 
(Ln−/IBCN−).
Expression of sCav-1 in primary breast tumors. sCav-1 expression has been evaluated in all the 189 
primary IBC cases examined. Myoepithelial cells and endothelium exhibited strong staining in all the samples 
examined, as expected, indicating a proper immunohistochemical reaction (see Fig. 2a–c).
In particular, 181 primary tumors (95.8%) [of which 134 cases were IBCs of No Special Type (IBCs-NST) 
(95.7%) and 47 cases were Invasive Lobular Cancers (ILCs) (95.9%)] stained positive for sCav-1 (67 with score 
2, 114 with score 1). 8 cases (4.2%) were negative (score 0).
Of the 189 cases, sCav-1 expression was lower in those tumors with axillary metastatic spread (IBCN +) 
compared to those limited to the breast (IBCN−), with a p-value close to statistical significance (p = 0.0610, see 
Fig. 3c).
In the attempt to stratify sCav-1 expression among the different subtypes, we have found: i) no significant 
difference between IBCs-NST and ILCs; ii) among IBCs-NST, a statistically significant correlation between loss of 
sCav-1 and presence of lymph node metastases in poorly differentiated carcinomas (p-value = 0.03, see Fig. 3d).
Recurrence rate and sCav-1 expression in primary IBCs. We have collected patients’ clinical data up 
until 20th of September 2020 (see Supplementary Table S1). According to these data: (i) 28 patients have been 
lost to follow-up (the loss to follow-up rate was quite low: ~ 15%); (ii) 13 patients with IBC-NST and 7 patients 
with ILC have relapsed; the total recurrence rate was 13% and, in particular: 12% for IBC NST and 16% for IBC 
ILC.
Interestingly, even if only ~ 4% of primary IBCs totally lacked the expression of sCav-1 (score 0), we have 
found that ~ 74% of the relapsed cases had only a weak expression of sCav-1 (score 1) regardless the histotype 
(10 of 13 were IBC-NST and 5 of 7 were ILC) (see Supplementary Table S2).
In addition, all relapsed cases were grade 3 or 2; none grade 1 tumors relapsed.
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In conclusion, our data are in line with the literature; indeed, sCav-1 loss in primary breast cancer is a nega-
tive prognostic factor and is common in high grade breast  cancer19.
Potential pitfalls. Selected samples represented a relatively small consecutively series in a mono-institu-
tional setting; this could represent a limitation to draw statistically significant conclusions about the correla-
tion between sCav-1 expression and patients outcomes, even if this is not the main aim of the present article. 
Moreover, this could be the reason for the lower rate of primary IBC sCav-1 negative in respect to the  literature18.
This research article would present preliminary results that support new insights on the potential role of 
sCav-1 in lymph node metastatic niche, paving the way for further investigations. However, data need to be 
validated in a wide well-studied and well-annotated multicentric cohort with a long term follow-up, in order to 
confirm envisaged scenarios.
Figure 1.  Illustration of fibroblast-like stromal cells in a lymph node. In the insets three examples of sCav-1 
positive cells in a normal lymph node. Together with endothelial cells (black arrow) and pericytes, fibroblast-like 
stromal cells, such as marginal reticular cells (white arrow) under the subcapsular sinus, fibroblastic reticular 
cells in the paracortex/T cell zone (*), and follicular dendritic cells in lymphoid follicles (arrowhead) constitute 
the stromal compartment of a lymph node. All IHC images magnification: 200x. Created with BioRender.com.
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Discussion
To date, the relationship between Cav-1 and cancer remains  controversial11. In the past, human studies exten-
sively focused on the role of Cav-1 in epithelial cancer cells reporting a significant increase in Cav-1 expression 
in malignant lesions than benign breast  tissue21–25. In recent decades, increasing attention has been paid to the 
expression of Cav-1 in the tumor stroma where its loss predicts poor  outcome15–17. In the present study, immu-
nohistochemistry performed on IBCs primary tumors demonstrated a considerable trend toward significance 
between a loss of sCav-1 and presence of lymph node metastases. Nevertheless, statistical significance is achieved 
when only poorly differentiated NST IBCs are considered. These data are in accordance to those from the litera-
ture, where a strong association was observed between a loss of sCav-1 and the presence of lymph node metas-
tases in triple negative  tumors19. This suggests that especially IBCs with aggressive behavior may be sensitive to 
sCav-1 regulation in their progression into metastatic disease. In contrast, at present there is still little knowledge 
regarding the expression of sCav-1 at metastatic sites. Here, DTCs survive and grow as metastasis in presence of a 
supportive tumor stroma, the so-called “metastatic niche”, whose evolution thus recapitulates stromal progression 
in the primary  tumor5. The formation of the metastatic niche can also be remotely induced by primary tumors 
before the arrival and establishment of DTCs: for such cases, the term “pre-metastatic niche” has been  coined26. 
This phenomenon has been described also for lymph nodes, where fibroblast-like stromal cells, together with 
bone marrow derived cells, play a crucial role to form these permissive  compartments6. The present study inves-
tigated the expression of sCav-1 in the tumor stroma of IBCs and in their corresponding axillary lymph nodes, 
in order to define any possible correlation with cancer metastasis. In accordance to Alevizos et al., sCav-1 was 
significantly less expressed in lymph node metastases than lymph nodes with reactive hyperplasia, of metastatic 
or non-metastatic cases, confirming that low expression of Cav-1 in fibroblast-like stromal cells of axillary lymph 
Figure 2.  Semiquantitative score of sCav-1 expression. (a) Absent (Score 0), (b) weak (Score 1) and (c) strong 
(Score 2) expression of sCav-1 in cancer associated fibroblasts (arrowhead) in primary invasive breast cancer. 
(d) Absent (Score 0), (e) weak (Score 1) and (f) strong (Score 2) expression of sCav-1 in fibroblast-like stromal 
cells (arrowhead) within metastatic lymph nodes; in the insets Pan-CK expression in metastatic cells. Internal 
positive controls: endothelial cells (black arrow) and myoepithelial cells (white arrow). All images magnification: 
×200.
Table 1.  Distribution of sCav-1 expression among IBC subtypes and corresponding lymph nodes (LN).  IBC-
NST invasive carcinoma of no special type, w.d. well differentiated, m.d. moderately differentiated, p.d. poorly 
differentiated, ILC invasive lobular carcinoma.
Score 2 Score 1 Score 0 Total IBC (LN)
IBC-NST(LN) 48(15) 86(51) 6(44) 140(110)
w.d.(LN) 16(2) 27(7) 2(0) 45(9)
m.d.(LN) 11(5) 32(9) 4(0) 47(14)
p.d.(LN) 21(8) 27(35) 0(44) 48(87)
ILC(LN) 19(23) 28(30) 2(19) 49(72)
Total IBC(LN) 67(38) 114(81) 8(63) 189(182)
5
Vol.:(0123456789)
Scientific Reports |         (2021) 11:2755  | https://doi.org/10.1038/s41598-021-82405-y
www.nature.com/scientificreports/
nodes correlates with high metastatic  potential27. Intriguingly, Celus et al. recently demonstrated in mouse mod-
els of lung and breast cancer metastasis that Cav-1 inhibition in the so-called metastasis-associated macrophages 
(MAMs) drives metastatic growth favoring angiogenesis by the restriction of vascular endothelial growth factor 
A/vascular endothelial growth factor receptor 1 (VEGF-A/VEGFR1) signaling and its downstream effectors at 
the metastatic  site28. A similar mechanism may be involved in humans. For the first time to our best knowledge, 
we described a statistically significant progressive loss of sCav-1 from normal/reactive axillary lymph nodes from 
tumors limited to the breast (Ln−/IBCN−) to metastatic axillary lymph nodes (Ln +), through normal/reactive 
axillary lymph nodes of tumors with axillary metastatic spread (Ln−/IBCN +). These data may suggest that Cav-1 
expressed by the stromal compartment of lymph nodes, somehow, may play a possible role in establishing the 
pre-metastatic niche in IBC. The lower expression of sCav-1, observed not only in lymph node metastases but 
also in close lymph nodes with reactive hyperplasia (Ln−/IBCN +), may hint at the possible role of the primary 
tumor or of the DTCs in the microenvironmental changes of loco-regional lymph nodes, contributing to the 
formation of these permissive compartments. In order to better investigate which of the two—the primary tumor 
or DTCs—were more likely to be involved, we included lymph nodes from patients with no history of cancer 
but with reactive hyperplasia (as negative control, NC), which showed consistently high expression of sCav-1. 
This would hint at the possibility that sCav-1 in lymph nodes might be modulated by DTCs, present in the same 
lymph node or in close vicinity, and not remotely by primary tumors at distance. Indeed, if the primary tumor 
exerted a permissive effect for the infiltration and growth of DTCs in the axilla, lymph nodes from patients with 
tumors limited to the breast (Ln−/IBCN−) should have shown a lower expression of sCav-1 than NC. Instead, the 
expression of sCav-1 in NC resulted even lower than axillary lymph nodes from patients with tumors limited to 
the breast (Ln−/IBCN−). According to this hypothesis, DTCs might in turn provide the permissive pre-metastatic 
niche in close lymph nodes. In 2005, Kaplan et al. firstly demonstrated that bone marrow-derived hematopoietic 
progenitor cells that express vascular endothelial growth factor receptor 1 (VEGFR1) home to tumor-specific 
pre-metastatic sites and form cellular clusters before the arrival of tumor  cells6. The authors also showed that 
VEGFR1 + cells express VLA-4 (also known as integrin α4β1), and that tumor-specific growth factors upregulate 
fibronectin—a VLA-4 ligand—in resident fibroblasts, providing a permissive niche for incoming tumor cells. 
Figure 3.  (a) Expression of sCav-1 in primary IBCs and lymph nodes. In contrast to primary IBCs (regardless 
the nodal status), a high number of metastatic lymph nodes (Ln +) showed score 0 staining for sCav-1. 
Ln + demonstrate significant lower expression of sCav-1 than lymph nodes without metastasis (Ln−). (b) sCav-1 
expression in lymph nodes. From right to left, sCav-1 is increasingly lost from lymph nodes with reactive 
hyperplasia from cases without nodal metastatic disease (Ln−/IBCN−), through non-metastatic lymph nodes 
from cases with nodal metastatic disease (Ln−/IBCN +), to Ln + ; lymph nodes of patients with no history of 
cancer (NC) show undoubtedly high expression of sCav-1, comparable to Ln−/IBCN−, even if slightly lower. 
(c) Correlation of sCav-1 expression in primary IBCs and nodal status. The histograms show how primary 
tumors with nodal metastasis (IBCN +) demonstrate lower expression of sCav-1 than primary tumors without 
metastasis (IBCN−), regardless the grade. (d) Correlation of sCav-1 expression in primary poorly differentiated 
(p.d.) IBCs of no special type (NST) and nodal status. The histograms show how IBCN + demonstrate 
statistically significant lower expression of sCav-1 than IBCN− in the NST p.d. subgroup. sCav-1 staining was 
scored semi-quantitatively as 0, 1 and 2 (see text).
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According to this, recent evidence suggest that tumor secreted factors modify perivascular cells to create a pro-
metastatic environment enriched in  fibronectin29. In 2008, Shi and Sottile showed how Cav-1-dependent β1 
integrin endocytosis is a critical regulator of fibronectin turnover; in particular, they demonstrated that Cav-1 
downregulation reduces both fibronectin and β1 integrin  endocytosis30. Within this scenario, a loss of expres-
sion of sCav-1 in lymph nodes may contribute to the localized deposition of fibronectin, providing permissive 
compartments for DTCs. In addition, sCav-1 has been recently described to promote the ability of dendritic 
cells (DC) to reach the lymph nodes and initiate CD8 + T cells response. Indeed, Oyarce et al. have reported that 
caveolin-1 expression increases upon maturation in DCs and promotes their migration to lymph nodes favoring 
the activation of CD8 + T cells. CD8 + T cells response represents a key mechanism against pathogens but also 
against solid tumors. To confirm this hypothesis the Authors demonstrated a reduction in CD8 + T cell response 
and antitumor protection in mice that received CAV−/−  DCs31. These data strongly suggest that a loss of expres-
sion of sCav-1 in lymph nodes may inhibit anti-tumor CD8 + T cells, thus favoring the initiating capacity of 
incoming DTCs. Finally, immunohistochemical studies of human breast cancer showed that specimens lacking 
sCav-1 overexpress key enzymes of the glycolytic pathway, such as PKM2 and  LDH32,33, thus generating, in the 
pre-metastatic niche, high quantities of energy metabolites (i.e. lactate and pyruvate) to feed the arriving DTCs. 
As a result, the loss of expression of sCav-1 in axillary lymph nodes may promote successful seeding of arriving 
cancer cells via at least three fascinating mechanisms: the increase of fibronectin deposition, the inhibition of 
anti-tumor CD8 + T cells and the increase of energy metabolites availability. Further studies are needed to better 
understand either the mechanisms through which a loss of sCav-1 may contribute to the regulation of metastatic 
niche formation or the mechanisms through which cancer cells induce the downregulation of sCav-1, a process 
currently still largely poorly understood.
In conclusion, our findings, in addition to supporting data from the literature, provide further and new 
evidence of a correlation between sCav-1 expression in lymph nodes and lymph node metastases, suggesting a 
possible role in the establishment of the pre-metastatic niche in breast cancer.
Further analyses on larger cohorts of patients with adequate number of lymph node metastases are required 
to validate these preliminary data definitely; moreover, functional studies in vitro are needed to study in depth 
the biological mechanisms underlying these preliminary observations.
Materials and methods
Case selection. 189 cases (53 with lymph node metastases and 136 without) were examined, from women 
with a median age of 57.55 years (range 31–89 years). All IBCs were classified according to 2019 World Health 
Organization (WHO) Classification into IBC-NST, graded according to the Nottingham Modification of the 
Bloom-Richardson system, and ILC (Table 2).
137 axillary lymph nodes were collected from 28 cases with axillary metastatic spread (IBCN +); among these, 
54 displayed metastasis (Ln +), 83 did not (Ln−/IBCN +). In addition, 45 axillary lymph nodes were collected 
from other 28 cases with tumors limited to the breast (Ln−/IBCN−). Therefore, three groups of study interest 
were delineated (Table 3): (i) metastatic axillary lymph nodes (Ln +); (ii) normal/reactive axillary lymph nodes 
of tumors with axillary metastatic spread (Ln−/IBCN +); (iii) normal/reactive axillary lymph nodes of tumors 
limited to the breast (Ln−/IBCN−).
Twenty normal/reactive axillary lymph nodes of patients admitted at our hospital for cardiac surgeries and 
with no history of cancer were included as negative controls (NC). All of the specimens studied were retrieved 
from the files of the Division of Surgical, Molecular, and Ultrastructural Pathology, University of Pisa (Italy) 
from January 2006 to January 2011.
sCav-1 was evaluated: (i) in lymph nodes, in fibroblast-like stromal cells classified as marginal reticular cells 
(below the sub-capsular sinus), fibroblastic reticular cells (of the paracortex/T cell zone) and follicular dendritic 
cells (of B follicles) (see Fig. 1); (ii) in IBCs, in fibroblasts scattered in the tumor stroma.
All investigations were conducted according to the principles expressed in the Declaration of Helsinki; this 
study was approved by the "Ethical Committee for the testing and evaluation of clinical study protocols in the 
North Wester Tuscany Area (CEAVNO)" (Prot. n: 14,835. Approval date: 11/04/2019). Written informed consent 
was obtained from each participant.
Table 2.  Patients selection: sex, median age and distribution of different subtypes of IBC.  F female, y years, 
IBC-NST invasive breast carcinoma of no special type, N +  number of cases with lymph node metastasis, w.d. 
well differentiated, m.d. moderately differentiated, p.d. poorly differentiated, ILC invasive lobular carcinoma.
Sex F
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Immunohistochemistry. Formalin-fixed, paraffin-embedded (FFPE) tissue blocks were cut into 4  µm 
thick sections. Slides were incubated with rabbit polyclonal anti-Caveolin-1 antibody (N20) (Santa Cruz CA, 
dilution 1:500) at 37 °C for 32 min (Ventana Benchmark XT staining system, Ventana Medical System-Roche) 
and developed in diaminobenzidine (DAB)—hydrogen peroxide for 10 min (ultraView Universal DAB kit, Ven-
tana Medical System-Roche). Finally, sections were counterstained with hematoxylin and mounted. The stain-
ing was scored semi-quantitatively as 0 (negative, in stromal cells), 1 (diffuse weak or strong in less than 30% of 
stromal cells) and 2 (strong in 30% or more of the stromal cells)20. Both membranous or combined membranous 
and cytoplasmic staining was used for Cav-1 expression evaluation. Positive staining of myoepithelial cells or 
endothelium, known to be abundant in Cav-1, served as an internal positive control.
Statistical analysis. The Chi-Square test was used to analyze the association between the different pheno-
types and Cav-1 expression. All statistical analyses were performed by means of Medcalc for Windows (Version 
12). A p-value of less than 0.05 was considered statistically significant.
Received: 9 May 2020; Accepted: 19 January 2021
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